Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

“…3 However, a good response to a booster dose of vaccine was observed. Experience with other meningococcal vaccines has shown that waning of bactericidal antibody titres was associated with a decline in vaccine effectiveness following infant vaccination with serogroup C meningococcal conjugate vaccines, 12 adolescent vaccination with an investigational outer membrane vesicle vaccine in Norway 13 and infant vaccination with the New Zealand outer membrane vesicle vaccine. 10,14 Predicting the potential impact of a decline in bactericidal antibodies on vaccine effectiveness following vaccination with 4CMenB is less straightforward.…”

Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

“…The rate of decline of antibodies to the OMV component of the vaccine are similar to those reported for the Norwegian OMV in 13-14 y-olds, in which efficacy corresponded to the GMT of hSBA. 16 However, the inclusion of the additional protein antigens in 4CMenB, and particularly the high persistence of antibodies to fHbp and NadA suggest that efficacy will be maintained for longer than with the OMV-only vaccines. Furthermore, some role for priming cannot be discounted as in many instances the interval between carriage acquisition relative and infective invasion may still afford adequate opportunity for the development of relevant bactericidal antibodies.…”

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

“…SBA activity was only observed with antibodies raised against OMVs prepared from N. meningitidis 44/76-SL when tested against itself. Bactericidal antibodies are undoubtedly a correlate of protection for meningococcal vaccines based on capsular polysaccharides 27 and are important predictors of protection provided by meningococcal OMV vaccines containing PorA, 28 which elicit bactericidal antibodies in both mice and humans. The good antibody response (as detected by ELISA) but lack of in vitro bactericidal activity in sera from mice and rabbits immunized with N. lactamica OMVs or N. meningitidis OMVs, is consistent with the suggestion that other protective mechanisms, such as opsonophagocytosis, may provide the strong cross-reactive protection seen previously with a mouse model of meningococcal disease, in which antibodies raised against N. lactamica OMVs protected against challenge with any of a range of serogroup B and C strains despite absence of any bactericidal responses.…”